Nektar Therapeutics Income Statement (2010-2025) | NKTR

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Revenue & cost
Revenue (Quarter)	23.65M	28.33M	24.92M	25.01M	24.82M	21.59M	23.62M	22.02M	21.59M	20.50M	24.14M	23.89M	21.64M	23.49M	24.12M	29.18M	10.46M	11.18M	11.79M	21.81M
Cost of Revenue (Quarter)	5.76M	7.67M	5.31M	6.16M	5.32M	5.12M	4.97M	6.23M	7.06M	6.99M	12.43M	10.56M	11.21M	9.74M	4.43M	19.34M		10.32M	10.30M	6.85M
Gross Profit (Quarter)	17.89M	20.66M	19.61M	18.85M	19.51M	16.47M	18.65M	15.79M	14.53M	13.51M	11.71M	13.32M	10.43M	13.75M	19.69M	9.84M	10.46M	0.85M	1.49M	14.96M
Operating items
Research & Development (Quarter)	95.60M	101.31M	103.74M	99.61M	107.25M	42.74M	33.59M	34.74M	30.47M	29.68M	24.07M	29.94M	27.41M	29.72M	35.03M	28.75M	30.48M	29.89M	27.25M	29.71M
Selling, General & Administrative (Quarter)	31.68M	29.55M	29.47M	32.14M	27.34M	20.52M	22.53M	21.94M	21.08M	17.87M	21.15M	17.32M	20.15M	20.51M	18.96M	17.14M	24.35M	17.07M	16.07M	11.19M
Restructuring Costs (Quarter)					1.48M	27.75M	8.53M	2.75M	1.60M	1.36M	0.65M	1.89M
Other Operating Expenses (Quarter)	5.76M	7.67M	5.31M	6.16M	5.32M	83.41M	13.27M	15.06M	103.16M	22.19M	23.14M	8.25M	-40.53M	-31.40M	-48.61M	126.51M	-50.37M	-42.84M	0.14M	8.57M
Operating Expenses (Quarter)	133.04M	138.53M	138.52M	137.92M	141.38M	174.42M	77.93M	74.49M	156.30M	71.10M	69.01M	57.40M	7.02M	18.84M	5.38M	172.39M	4.46M	4.11M	43.46M	49.47M
Operating Income (Quarter)	-109.39M	-110.20M	-113.60M	-112.91M	-116.56M	-152.84M	-54.30M	-52.47M	-134.71M	-50.60M	-44.86M	-33.51M	-35.43M	-49.77M	-34.34M	14.35M	-44.53M	-36.23M	-31.67M	-27.66M
EBIT (Quarter)	-109.39M	-110.20M	-113.60M	-112.91M	-116.56M	-152.84M	-54.30M	-52.47M	-134.71M	-50.60M	-44.86M	-33.51M	-35.43M	-49.77M	-34.34M	14.35M	-44.53M	-36.23M	-31.67M	-27.66M
Non-operating items
Interest & Investment Income (Quarter)									4.33M	4.85M	5.21M	4.62M	4.22M	3.90M	3.44M	2.94M	2.87M	1.97M	2.82M	2.78M
Other Non Operating Income (Quarter)	-1.60M	-2.71M	0.13M	-2.55M	33.43M		2.05M		-0.30M	0.74M	-0.34M	-6.35M	-0.10M	-0.04M	-0.12M	-0.14M	0.27M	0.26M	-0.12M	-0.04M
Non Operating Income (Quarter)	1.41M	0.84M	-16.00M	-79.56M	26.29M	1.10M	2.05M	-4.08M	-2.37M	0.74M	-0.34M	-2.27M	-1.41M	-0.04M	-2.70M	6.27M	-1.83M	-3.17M	-3.35M	-0.70M
Net income details
EBT (Quarter)	-122.88M	-125.16M	-129.59M	-146.81M	-90.27M	-158.97M	-59.20M	-56.54M	-137.08M	-51.17M	-45.90M	232.89M	-36.84M	-52.32M	-37.05M	7.00M	-46.37M	-39.40M	-35.02M	-34.70M
Tax Provisions (Quarter)	0.09M	0.36M	0.11M	0.10M	0.13M	0.10M	-0.15M	0.44M	-0.06M	-0.05M	-0.06M	0.11M	-0.04M	0.05M	0.01M	-0.26M	0.05M	-0.19M	-0.03M	0.03M
Profit After Tax (Quarter)	-122.97M	-125.52M	-129.71M	-145.65M	-90.39M	-159.07M	-59.05M	-59.69M	-137.02M	-51.12M	-45.84M	-42.08M	-36.80M	-52.36M	-37.06M	7.26M	-50.88M	-41.59M	-35.52M	-36.08M
Equity Income (Quarter)																	-4.46M	-2.39M	-0.53M	-1.35M
Income from Continuing Operations (Quarter)	-122.97M	-125.52M	-129.71M	-146.91M	-90.39M	-159.07M	-59.05M	-56.98M	-137.02M	-51.12M	-45.84M	232.78M	-36.80M	-52.36M	-37.06M	7.26M	-46.42M	-39.21M	-34.99M	-34.73M
Consolidated Net Income (Quarter)	-122.97M	-125.52M	-129.71M	-146.91M	-90.39M	-159.07M	-59.05M	-56.98M	-137.02M	-51.12M	-45.84M	232.78M	-36.80M	-52.36M	-37.06M	7.26M	-46.42M	-39.21M	-34.99M	-34.73M
Income towards Parent Company (Quarter)	-122.97M	-125.52M	-129.71M	-146.91M	-90.39M	-159.07M	-59.05M	-56.98M	-137.02M	-51.12M	-45.84M	232.78M	-36.80M	-52.36M	-37.06M	7.26M	-46.42M	-39.21M	-34.99M	-34.73M
Net Income towards Common Stockholders (Quarter)	-122.97M	-125.52M	-129.71M	-146.91M	-90.39M	-159.07M	-59.05M	-56.98M	-137.02M	-51.12M	-45.84M	232.78M	-36.80M	-52.36M	-37.06M	7.26M	-46.42M	-39.21M	-34.99M	-34.73M
Additional items
EPS (Basic) (Quarter)	-0.68	-0.69	-0.70	-790.00	-0.49	-0.85	-0.31	-0.32	-0.73	-0.27	-0.24	-0.22	-0.19	-3.76	-2.66	0.59	-0.24	-2.95	-1.87	-1.59
EPS (Weighted Average and Diluted) (Quarter)	-0.68	-0.69	-0.70	-790.00	-0.49	-0.85	-0.31	-0.32	-0.73	-0.27	-0.24	-0.22	-0.19	-3.76	-2.66	0.59	-0.24	-2.95	-1.87	-1.59
Shares Outstanding (Weighted Average) (Quarter)	181.37M	182.04M	184.11M	183.30M	185.85M	186.80M	186.77M	187.14M	188.88M	189.27M	190.41M	190.00M	194.75M	13.45M	13.62M	13.71M	210.92M	14.07M	15.72M	16.87M
Shares Outstanding (Diluted Average) (Quarter)	181.37M	182.70M	182.74M	183.30M	185.85M	186.32M	186.77M	187.14M	188.88M	189.27M	190.41M	190.00M	194.75M	13.45M	13.95M	13.71M	210.92M	14.09M	15.72M	16.87M
EBITDA (Quarter)	-109.39M	-110.20M	-113.60M	-112.91M	-116.56M	-152.84M	-54.30M	-52.47M	-134.71M	-50.60M	-44.86M	-33.51M	-35.43M	-49.77M	-34.34M	14.35M	-44.53M	-36.23M	-31.67M	-27.66M
Interest Expenses (Quarter)
Tax Rate (Quarter)	-0.07%	-0.29%	-0.09%	-0.07%	-0.14%	-0.06%	0.26%	-0.77%	0.05%	0.09%	0.13%	0.05%	0.10%	-0.09%	-0.02%	-3.70%	-0.11%	0.48%	0.09%	-0.09%

Research Tools

Nektar Therapeutics Income Statement (2010-2025) | NKTR

Create an account

Sign In

Reset Password